Investor Relations
Company Overview
Avalo Therapeutics, Inc. (AVTX) is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in the areas of Immunology, Immuno-oncology, and Rare Genetic Diseases.
Latest News
Sep 20, 2021 • 7:00 AM EDT
Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
Sep 17, 2021 • 9:11 AM EDT
Sep 14, 2021 • 10:23 PM EDT
Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
Stock Information
Nasdaq: AVTX
Avalo Therapeutics, Inc.
Price
Change
Volume
Day Range
52 Week Range